-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Mindray Medical issued an announcement stating that the company intends to use its wholly-owned subsidiary Mindray Global (Hong Kong) Co.
, Ltd.
(English name is MR Global (HK) Limited, hereinafter referred to as “Hong Kong Global” or “wholly-owned subsidiary”) and Hong Kong The global wholly-owned subsidiary Mindray Medical Netherlands B.
V.
(hereinafter referred to as "Mindray Holland" or "Wholly Owned Sun Company") acquired the following equity in the form of cash (1) SummaEquity AB's subordinate fund and Spartak Co-Investment AB held Hytest Invest Oy (hereinafter referred to as the "target company") 100% equity, (2) all minority equity held by Maria Severina and Alexey Katrukha and certain natural person shareholders in Hytest Holding Oy, a subsidiary of the target company, (3) Maria Severina and Jukka Lehikoinen hold all minority shares in Hytest Oy, an indirect subsidiary of the target company, and (4) 4,790,643 options of Hytest Holding Oy held by some individual shareholders and natural persons, thereby acquiring the target company and its subsidiaries 100% equity (hereinafter referred to as "the transaction"), the total purchase price is estimated to be approximately 545 million euros, and the final transaction amount is subject to confirmation at the time of actual delivery
.
After the completion of this transaction, the company will indirectly hold 100% of the equity of Hytest Invest Oy and its subsidiaries